Dabrafenib (GSK2118436)

Catalog No.S2807

Dabrafenib (GSK2118436) Chemical Structure

Molecular Weight(MW): 519.56

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM in cell-free assays, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.

Size Price Stock Quantity  
In DMSO USD 180 In stock
USD 90 In stock
USD 130 In stock
USD 170 In stock
USD 270 In stock
USD 400 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • A375P cells were treated with vehicle, the BRAF inhibitor GSK2118436, the MEK inhibitor GSK1120212, 10 uM HCQ, or the indicated combinations. Shown are 48-hour immunoblots directed against the indicated proteins.

    J Clin Invest 2014 24(3), 1406-17. Dabrafenib (GSK2118436) purchased from Selleck.

    Levels of pERK and tERK in the CLL cells derived from PBMC were measured by Western blot. We used vemurafenib, dabrafenib, and trametinib (0.07 uM) as indicated. One of 3 independent experiments with similar results is shown. CLL cells exposed to dabrafenib or vemurafenib had an elevated pERK/tERK ratio as compared with vehicle (P < 0.01).

    J Clin Invest 2014 124(11), 5074-84. Dabrafenib (GSK2118436) purchased from Selleck.

  • The effects of inhibitors of mutant BRAFV600 inhibitor dabrafenib on cancer cell growth were evaluated by the MTT assay. Cell growth inhibition of FRO and SW1736 cell lines induced by dabrafenib.

    Transl Res 2014 10.1016/j.trsl.2014.06.005. Dabrafenib (GSK2118436) purchased from Selleck.

    Dabrafenib alleviates acetaminophen-induced hepatotoxicity in mice. Mice were treated with 300 mg/kg acetaminophen (i.p.), with or without pretreatment with 300 mg/kg or 100 mg/kg dabrafenib (p.o.).TUNEL staining for nuclear DNA fragmentation in mouse liver cells.

    Cell Death Dis 2014 5, e1278. Dabrafenib (GSK2118436) purchased from Selleck.

  • Western blot analysis of p-Erk and total ERK in A375 melanoma cell line after treatment with different doses of Dabrafenib for 48 hours (A). p-ERK signal was normalized with total ERK signal (B), SD and means of the normalized p-ERK values were reported.

    PLoS One, 2016, 11(3):e0152104. Dabrafenib (GSK2118436) purchased from Selleck.

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM in cell-free assays, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.
Targets
B-Raf (V600E) [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
C-Raf [1]
(Cell-free assay)
0.8 nM 3.2 nM 5.0 nM
In vitro

Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-RafV600E kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-RafV600E. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MUfLbY5ie2ViQYPzZZk> MoPkTY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFjpd{B1[WepZXSgRk1T[WZiVk[wNGUhdXW2YX70JIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDpcpNm[3RiY3XscJMh[29vZYjwdoV{e2mwZzDDSGM{PyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBjcW:2aX75cIF1\WRvTVXLJJBzd3SnaX6gdIhwe3Cqb4L5cIF1cW:wIHL5JGFteGijU3Py[YVvKGG|c3H5JJdqfGhiSVO1NEBw\iByLkCwNFch|ryP M4P6b|I1QTByNkez
SK-MEL-28 MWnLbY5ie2ViQYPzZZk> MnTBNUBp NWXUW5ZIUW6qaXLpeIlwdiCxZjDCMXJi\iCYNkCwSUBufXSjboSgbY4hcHWvYX6gV2suVUWOLUK4JINmdGy|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKEWUSzDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODB2IN88US=> M1fmR|I1QTByNkez
HepG2 MYDLbY5ie2ViQYPzZZk> MV\Jcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfCCrbjDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCHUlugdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjByNDFOwG0> NHTrUnMzPDlyME[3Ny=>
COLO205 NGXIdHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjXTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRMkC1JINmdGxicILvcIln\XKjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFch|ryP NWXPVWdzOjR7MEC2O|M>
HepG2 MUXGeY5kfGmxbjDBd5NigQ>? MlTXOFUhdWmw MmT5SG1UVw>? M1TJc2lvcGmkaYTpc44hd2ZiQXzrOUBqdiCWR1[tZoV1[S2|dHnteYxifGWmIHj1cYFvKEincFeyJINmdGy|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKFOvYXSyJJBpd3OyaH;yfYxifGmxbjD0doVifGWmIH\vdkA1PSCvaX7zJJBzcW:{IITvJHRITi2kZYThJJN1cW23bHH0bY9vKG2nYYP1doVlKGGodHXyJFYxKG2rboOgZpkhd2S7c4PlfUBjdG:2IIPjZY5v\XJiYX7hcJl{cXNid3n0bEBKSzVyIH;mJFMvPyEQvF2= MlHwNlQ6ODB4N{O=
HFF MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPYTXQyOCEQvF2= M4LaTFczKGh? MUPEUXNQ NIfFSFZKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44hd2ZiaIXtZY4hUE[IIHPlcIx{KGijcnLvdolv\yC5aXzkJJR6eGViQj3SZYYhf2m2aDDJR|UxKG:oIEOg{txO NW\JO2p[OjN6NESwN|g>
SK-MEL-28 Mo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\oNVAh|ryP MV[3NkBp M4fHUmROW09? M2jwSGlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62LXTybZZmdiCVSz3NSWwuOjhiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjB2MzFOwG0> Ml\oNlM5PDRyM{i=
A375P-F11 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;LcoEyOCEQvF2= NHTtcYc4OiCq NGHwZpJFVVOR MYLJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfC2mcnn2[Y4hSTN5NWCtSlEyKGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4xPzFizszN NYHwbJVpOjN6NESwN|g>
MALME-3M MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvSNVAh|ryP NGO5R2g4OiCq MXvEUXNQ M13JcWlEPTB;MTDuUS=> NHW4N3AzOzh2NECzPC=>
UACC-62 NIDTZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Xyc|ExKM7:TR?= NYS0S4JsPzJiaB?= MkXuSG1UVw>? NW\WOo1OUUN3ME2xJI5O NUe0SHdlOjN6NESwN|g>
C32TG MlXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X1SlExKM7:TR?= MnvRO|IhcA>? NFXRR4xFVVOR NX3HflNuUUN3ME2xJI5O NI\0cGEzOzh2NECzPC=>
SK-MEL-1 M2HEdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrtNVAh|ryP MUe3NkBp NFXiWo1FVVOR MWDJR|UxRTJibl2= MonjNlM5PDRyM{i=
M14 NUj3b4h5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYGxNEDPxE1? NXSweHpVPzJiaB?= MUTEUXNQ NH:4NnpKSzVyPUKgcm0> Mo\ENlM5PDRyM{i=
SK-MEL-28 NU\NV|JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnSwNVAh|ryP NYTQW21lPzJiaB?= MU\EUXNQ MmTpTWM2OD1|IH7N NYnEWXQxOjN6NESwN|g>
A375 M4PCNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHS[XkyOCEQvF2= MV[3NkBp M4\ITGROW09? NIfyfHBKSzVyPUSgcm0> MlS4NlM5PDRyM{i=
DU-4475 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHL2PZIyOCEQvF2= M4\zU|czKGh? MmPJSG1UVw>? MnHLTWM2OD13IH7N M3LMXlI{QDR2MEO4
UACC-257 NX7PSm5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj2NVAh|ryP NV;ZNXZ6PzJiaB?= MV3EUXNQ NUTmV|ROUUN3ME22JI5O NVLETm1SOjN6NESwN|g>
Colo 205 M{jqZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnKxNVAh|ryP MkjMO|IhcA>? NU\nVVVJTE2VTx?= M2m5[mlEPTB;NzDuUS=> NF2wSFAzOzh2NECzPC=>
SK-MEL-3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\yN|ExKM7:TR?= NVnCZYRtPzJiaB?= NXHXcJZvTE2VTx?= M4jmXWlEPTB;NzDuUS=> MVGyN|g1PDB|OB?=
SH-4 M2flOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW[yZoFtOTBizszN Mn;XO|IhcA>? M1PoOGROW09? NVLCO|RuUUN3ME24JI5O NFLwO4wzOzh2NECzPC=>
A101D NHv1UFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;1NVAh|ryP MnvxO|IhcA>? NH7NV4pFVVOR M2rD[2lEPTB;OTDuUS=> NUPMfJo6OjN6NESwN|g>
ES-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYCxNEDPxE1? Mn;mO|IhcA>? MlPGSG1UVw>? NY\Fdnc6UUN3ME21N{BvVQ>? MYOyN|g1PDB|OB?=
HT-29 M4HYN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{KzVVExKM7:TR?= MYm3NkBp MlHFSG1UVw>? M1\aT2lEPTB;Nk[gcm0> M3TUeFI{QDR2MEO4
SW1417 NFLZbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfYRXUyOCEQvF2= Mn\HO|IhcA>? M2fjcGROW09? M{HldWlEPTB;MUW4JI5O M2\EN|I{QDR2MEO4
SW872 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHDNVAh|ryP MmfGO|IhcA>? NXXSNlBzTE2VTx?= Mmq0TWM2OD1|N{egcm0> M{LZRVI{QDR2MEO4
RKO MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXyxNEDPxE1? NHnGfJk4OiCq M1;mdGROW09? NVzO[oFSUUN3ME2yMlUzOiEQvF2= NGfKR4ozOzh2NECzPC=>
A673 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWKxNEDPxE1? NF2zOo44OiCq NULnUpozTE2VTx?= NYXRV3gxUUN3ME2xNEDPxE1? NGLVUmczOzh2NECzPC=>
GCT NYK1XopyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzWOWcyOCEQvF2= MXm3NkBp MYnEUXNQ NHTudmVKSzVyPUGwJO69VQ>? NGT3UlEzOzh2NECzPC=>
WM-115 M3\xc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1m2bVExKM7:TR?= M1KzdFczKGh? NH\6cIxFVVOR NFjTeG9KSzVyPUWgcm0> NF3rfXEzOzh2NECzPC=>
YUMAC NWPNcWlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW[xNEDPxE1? MoLXO|IhcA>? MnTBSG1UVw>? M{PMcGlEPTB;NTDuUS=> NGDqeHQzOzh2NECzPC=>
OV-90 Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DSeFExKM7:TR?= M{jDb|czKGh? NIrTV25FVVOR NYrob4dnUUN3ME2yPUBvVQ>? NX7UOWI6OjN6NESwN|g>
NCI-H508 MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjBOVI6OTBizszN NH\RXGg4OiCq MXrEUXNQ MoS4TWM2OD1zMDFOwG0> NI\nUG0zOzh2NECzPC=>
MDA-MB-231 NGnyOlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7ZUW0yOCEQvF2= NWD5U5l[PzJiaB?= NFjiSFFFVVOR MXvJR|UxRTFyIN88US=> NV\menZPOjN6NESwN|g>
SW756 NFXrVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTZWJlrOTBizszN NGntWWI4OiCq NXnwZ|RbTE2VTx?= MVPJR|UxRTFyIN88US=> NVn1cpRzOjN6NESwN|g>
SW-837 NXPDOYE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vQSlExKM7:TR?= M3rkSVczKGh? NHO1OVVFVVOR MlzPTWM2OD1zMDFOwG0> MVOyN|g1PDB|OB?=
UMUC-3 NGjIO2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPG[GwyOCEQvF2= MmXCO|IhcA>? NXzHUGVxTE2VTx?= M4XhTmlEPTB;MUCg{txO NYLnNmJDOjN6NESwN|g>
LS-174T M1jUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\WNVAh|ryP M1TzS|czKGh? Mof3SG1UVw>? Mon2TWM2OD1zMDFOwG0> MkXvNlM5PDRyM{i=
A549 NFXifnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUSxZ3dHOTBizszN MUG3NkBp M17ufGROW09? MXHJR|UxRTFyIN88US=> MnfkNlM5PDRyM{i=
SHP-77 NEPN[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXDSoZbOTBizszN NFftVm04OiCq MnriSG1UVw>? Mo[2TWM2OD1zMDFOwG0> MXiyN|g1PDB|OB?=
SW480 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnjTJpGOTBizszN MmXHO|IhcA>? NWH5cFFCTE2VTx?= M4juVmlEPTB;MUCg{txO M2nzbVI{QDR2MEO4
DLD-1 MnTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjMR3VwOTBizszN MXS3NkBp NVyzWGRSTE2VTx?= NVzDN3A3UUN3ME2xNEDPxE1? M{HqO|I{QDR2MEO4
HCT-116 NFL1SoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfjbYZSOTBizszN MlH6O|IhcA>? NV6wXmxKTE2VTx?= MnjPTWM2OD1zMDFOwG0> MX6yN|g1PDB|OB?=
NCI-H747 M121R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWOxNEDPxE1? Mm[wO|IhcA>? MY\EUXNQ MlS2TWM2OD1zMDFOwG0> M{iyZ|I{QDR2MEO4
T-84 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;uVHQyOCEQvF2= MUi3NkBp NFP5NGxFVVOR M3K2XGlEPTB;MUCg{txO MlW3NlM5PDRyM{i=
NCI-H460 M1TwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjScolNOTBizszN NEjndXo4OiCq M1HrPGROW09? NFL6PVdKSzVyPUGwJO69VQ>? M1ThUFI{QDR2MEO4
Calu-6 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\HfVExKM7:TR?= MYK3NkBp NGfLNYZFVVOR M4[2dWlEPTB;MUCg{txO MXuyN|g1PDB|OB?=
HCC-2998 NXnObW5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljaNVAh|ryP M1XsNlczKGh? M3LIbGROW09? M17ySWlEPTB;MUCg{txO NXny[m91OjN6NESwN|g>
LS1034 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLnNVAh|ryP NV3XbGRoPzJiaB?= NYnTVlJUTE2VTx?= NYraU3huUUN3ME2xNEDPxE1? MWWyN|g1PDB|OB?=
CHP-212 M{O3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jsUVExKM7:TR?= NGXufIo4OiCq MYjEUXNQ NUPlR2JzUUN3ME2xNEDPxE1? NGPR[Y0zOzh2NECzPC=>
SK-N-AS MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmC0NVAh|ryP MnPFO|IhcA>? MXjEUXNQ NIW0N41KSzVyPUGwJO69VQ>? NWDUdnd2OjN6NESwN|g>
BFTC-905 M{TxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\6Wo81OTBizszN MYK3NkBp NHWxV3dFVVOR MW\JR|UxRTFyIN88US=> MkPmNlM5PDRyM{i=
HuT78 NFHO[HNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj1b4YyOCEQvF2= MYG3NkBp NU\uWoRCTE2VTx?= NEflWI5KSzVyPUWyJI5O M4n1O|I{QDR2MEO4
RPMI-8226 NVvlV|R5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVW1RYRNOTBizszN NUK5cJFyPzJiaB?= NITyN5pFVVOR M3LafWlEPTB;Mk[zJI5O NYnPVIFjOjN6NESwN|g>
BC-3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;q[XZVOTBizszN MYq3NkBp M{DwO2ROW09? NFvkPHJKSzVyPUK3O{BvVQ>? M37hTFI{QDR2MEO4
ACHN MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TWUlExKM7:TR?= M1PxdFczKGh? MoLJSG1UVw>? NGHmdnBKSzVyPUK5OEBvVQ>? MYiyN|g1PDB|OB?=
JRT3-T35 NV\zZVc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF70[pgyOCEQvF2= NHqwTZM4OiCq Mmj0SG1UVw>? NIX2PJlKSzVyPUK5OUBvVQ>? MnX4NlM5PDRyM{i=
SK-MES-1 NYDXOnZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jDTlExKM7:TR?= M2XLRlczKGh? NFnDOW1FVVOR NYD5NXF4UUN3ME2zNlkhdk1? NVHVdmROOjN6NESwN|g>
CESS NGmzPVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVmxNEDPxE1? MUG3NkBp M4naWWROW09? NXPpV4ZZUUN3ME20PVchdk1? M2nnU|I{QDR2MEO4
H4 Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlz5NVAh|ryP M1PCNVczKGh? NIn0THVFVVOR NUXYOWhGUUN3ME22NVkhdk1? M4\iZVI{QDR2MEO4
BC-1 NHz5UHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PHUlExKM7:TR?= MYG3NkBp M3rhOGROW09? MWHJR|UxRTdyNDDuUS=> NXXPcY1nOjN6NESwN|g>
DB MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2niZlExKM7:TR?= NYW0VZJGPzJiaB?= NF\CUY9FVVOR MVvJR|UxRTh5MzDuUS=> NW\2TWo1OjN6NESwN|g>
RPMI-6666 M1nTSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2njNFExKM7:TR?= MkfUO|IhcA>? NFLTfHlFVVOR M2XFVmlEPTB;OUK4JI5O M4jHUlI{QDR2MEO4
MC/CAR M4nZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7SNVAh|ryP MXK3NkBp NG\vOXlFVVOR NYHaSVdPUUN3ME2xMlAxOiEQvF2= MViyN|g1PDB|OB?=
SNU-1 MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fDdFExKM7:TR?= NYTHc5RuPzJiaB?= NG\ZbVhFVVOR MXLJR|UxRTFwNUCxJO69VQ>? MVGyN|g1PDB|OB?=
CEM/C1 NHrUeZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPDNXAyOCEQvF2= NFu1c|Q4OiCq NUnHcoE{TE2VTx?= MofTTWM2OD1zLke3N{DPxE1? MYWyN|g1PDB|OB?=
GDM-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljkNVAh|ryP M{DHd|czKGh? MnrhSG1UVw>? M1fJOWlEPTB;MT65PVch|ryP NEn4c2ozOzh2NECzPC=>
HT-1080 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTwNVAh|ryP M1fGdlczKGh? M4DEXmROW09? NIDZTVNKSzVyPUKuNFA1KM7:TR?= NH30TXYzOzh2NECzPC=>
HL-60 NGrDeXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\oOoR7OTBizszN M1rIOlczKGh? NVPJOFhlTE2VTx?= MojBTWM2OD1{LkG3PEDPxE1? NVvSW5NsOjN6NESwN|g>
C3A NY\IbJIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonwNVAh|ryP MnfmO|IhcA>? MnT4SG1UVw>? M4TRXGlEPTB;NT60NVQh|ryP M4\1XFI{QDR2MEO4
MES-SA Ml;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV2xNEDPxE1? NGrs[mw4OiCq M17FbmROW09? MYLJR|UxRTZwOUi5JO69VQ>? NXKwbZNqOjN6NESwN|g>
22Rv1 NVr0PFRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2O5W|ExKM7:TR?= MYK3NkBp MXnEUXNQ MYHJR|UxRTFyIN88US=> M{X1eFI{QDR2MEO4
647-V NHXm[2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;jNVAh|ryP MVK3NkBp MXnEUXNQ NHPLTVJKSzVyPUGwJO69VQ>? NY[2ZWF6OjN6NESwN|g>
786-O NGr3VGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPNboNYOTBizszN NX\YRZVMPzJiaB?= MU\EUXNQ MWLJR|UxRTFyIN88US=> NFmxd3ozOzh2NECzPC=>
A172 NEj3b2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MluwNVAh|ryP NFPSR5M4OiCq NV7nZ4RmTE2VTx?= M1LjWmlEPTB;MUCg{txO NXjFW3FtOjN6NESwN|g>
A204 NHL1TWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TXOlExKM7:TR?= M1\iWVczKGh? MV\EUXNQ MVLJR|UxRTFyIN88US=> MXSyN|g1PDB|OB?=
A427 M4rid2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSxNEDPxE1? M4DjNFczKGh? MV;EUXNQ Mn[4TWM2OD1zMDFOwG0> NIO0RnQzOzh2NECzPC=>
A431 NYjyWoRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3NPY0yOCEQvF2= NEC0Nm04OiCq MnH0SG1UVw>? MVnJR|UxRTFyIN88US=> M{j4N|I{QDR2MEO4
A2780 NFjZd4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmxNEDPxE1? M{\jb|czKGh? MVXEUXNQ MVLJR|UxRTFyIN88US=> M2GxfVI{QDR2MEO4
ARH-77 NXfkZoI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHyTG9nOTBizszN NELZb4E4OiCq MYjEUXNQ MmTWTWM2OD1zMDFOwG0> MkLQNlM5PDRyM{i=
Be(2)C NX3FS2pxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrGNVAh|ryP NUH5UoVwPzJiaB?= M1PvVmROW09? M4DFRmlEPTB;MUCg{txO M1fFPVI{QDR2MEO4
BT-20 NEXVeplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIf6fIQyOCEQvF2= NYH2dXdrPzJiaB?= MlLiSG1UVw>? NWr5WpNDUUN3ME2xNEDPxE1? MUGyN|g1PDB|OB?=
BxPc3 M1j1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzNVVFGOTBizszN NWP3W3d[PzJiaB?= NF3LXIFFVVOR M{LtcmlEPTB;MUCg{txO NIDadnczOzh2NECzPC=>
C-4 I NInDd29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX[xNEDPxE1? MVK3NkBp MUTEUXNQ MYDJR|UxRTFyIN88US=> MnHVNlM5PDRyM{i=
C33A MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYKxNEDPxE1? MYK3NkBp MnP5SG1UVw>? MYHJR|UxRTFyIN88US=> MWWyN|g1PDB|OB?=
CAL-27 NUXPUFI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYixNEDPxE1? M3rjcFczKGh? NGrVdGhFVVOR MX\JR|UxRTFyIN88US=> M3nOOlI{QDR2MEO4
CAL-62 NIH0XJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHDOGMyOCEQvF2= NEXyWZI4OiCq MoXUSG1UVw>? NXy0VWdpUUN3ME2xNEDPxE1? MWCyN|g1PDB|OB?=
Calu-3 NUexTYx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFr4ZZQyOCEQvF2= NYjmN5J1PzJiaB?= NWPSU5pUTE2VTx?= NGT5THFKSzVyPUGwJO69VQ>? MnTrNlM5PDRyM{i=
CaOV3 M{n1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUmxNEDPxE1? MnLXO|IhcA>? NEXZO2pFVVOR Mk\zTWM2OD1zMDFOwG0> M17WbFI{QDR2MEO4
CGTHW1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTBNpIyOCEQvF2= MXG3NkBp MnPzSG1UVw>? NGK2ZmZKSzVyPUGwJO69VQ>? MmfiNlM5PDRyM{i=
CHL-1 M2TMdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XUNFExKM7:TR?= M3XDU|czKGh? M4K3bmROW09? M{jnXWlEPTB;MUCg{txO M4HVblI{QDR2MEO4
Colo320DM MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTR[ZFbOTBizszN Ml7tO|IhcA>? Ml3OSG1UVw>? MWXJR|UxRTFyIN88US=> NVPGcYdTOjN6NESwN|g>
Colo704 M{f4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[xNEDPxE1? MXK3NkBp Mk\QSG1UVw>? M3TDTGlEPTB;MUCg{txO MXiyN|g1PDB|OB?=
COR-L23 M{XNO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{K4VVExKM7:TR?= MoPoO|IhcA>? NGnEWo5FVVOR NF3Cc5ZKSzVyPUGwJO69VQ>? M2nXelI{QDR2MEO4
CRO-AP2 MkWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rNOFExKM7:TR?= NEmzZmw4OiCq MlTHSG1UVw>? NGji[FJKSzVyPUGwJO69VQ>? M{LURVI{QDR2MEO4
Daudi NX[wOYJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NECyPYQyOCEQvF2= MVe3NkBp M3HldmROW09? NHXIOlFKSzVyPUGwJO69VQ>? NIXxXYkzOzh2NECzPC=>
DOTC 24510 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYSxNEDPxE1? MkfhO|IhcA>? M1TuWGROW09? MoHSTWM2OD1zMDFOwG0> M1\Q[lI{QDR2MEO4
DU-145 NGX2fHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\tNVAh|ryP M2W2UlczKGh? NXzYWotQTE2VTx?= NF6zZ|VKSzVyPUGwJO69VQ>? NUDLfnl4OjN6NESwN|g>
EB-3 NIjscoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXGbo06OTBizszN M17TTVczKGh? M4TBWmROW09? NH\TdGFKSzVyPUGwJO69VQ>? NXO0fVEyOjN6NESwN|g>
EFM-19 M3vrPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVmxNEDPxE1? M1HxWVczKGh? NG\3XZpFVVOR MlG2TWM2OD1zMDFOwG0> NHrEe|QzOzh2NECzPC=>
EKVX NXPxXWlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTFNVAh|ryP MkDDO|IhcA>? MXvEUXNQ M{D1d2lEPTB;MUCg{txO MoSxNlM5PDRyM{i=
FaDu M37sO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\vO5EyOCEQvF2= MUS3NkBp MmrwSG1UVw>? NYfmSFh2UUN3ME2xNEDPxE1? NWPuN4JCOjN6NESwN|g>
G401 NFOxN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInBUnAyOCEQvF2= MWS3NkBp Mny0SG1UVw>? NEe0O|lKSzVyPUGwJO69VQ>? M2riVlI{QDR2MEO4
HCC-70 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYOxNEDPxE1? MUO3NkBp MojiSG1UVw>? MUDJR|UxRTFyIN88US=> MnjtNlM5PDRyM{i=
HCC-1954 M4qxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[yNVAh|ryP M1e1blczKGh? MVXEUXNQ NYXF[2ZxUUN3ME2xNEDPxE1? NGT4RZMzOzh2NECzPC=>
Hela MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUixNEDPxE1? M1rKZVczKGh? MUfEUXNQ M1Pqb2lEPTB;MUCg{txO MkTXNlM5PDRyM{i=
Hep3B NUDWOpVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEm5dHQyOCEQvF2= M4XqZVczKGh? MlXqSG1UVw>? MkD1TWM2OD1zMDFOwG0> NUnhfll5OjN6NESwN|g>
HMCB NEjISWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7uW4UyOCEQvF2= M2TNZVczKGh? Mn34SG1UVw>? NEfZWplKSzVyPUGwJO69VQ>? M33jZVI{QDR2MEO4
HN5 NVzaT|hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUixNEDPxE1? NEHnUI84OiCq M2XkbmROW09? MWPJR|UxRTFyIN88US=> NWroWoR5OjN6NESwN|g>
HOS NELmdXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVGxNEDPxE1? NFLuV3E4OiCq NGjqT3lFVVOR M{C0cWlEPTB;MUCg{txO MkKxNlM5PDRyM{i=
HPAF-II NGX4[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVGxNEDPxE1? NEnjSWM4OiCq MYXEUXNQ M2q3dWlEPTB;MUCg{txO MWOyN|g1PDB|OB?=
Hs746.T MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D3dFExKM7:TR?= MlTKO|IhcA>? MlHDSG1UVw>? MWPJR|UxRTFyIN88US=> NELMflEzOzh2NECzPC=>
HT NYHyUHI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7ub|RbOTBizszN M3XyflczKGh? NIqzeY5FVVOR NVfZ[4hEUUN3ME2xNEDPxE1? NUnkeZdNOjN6NESwN|g>
HT-3 M4jZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnL4NVAh|ryP M4LaNlczKGh? NHjmN|JFVVOR MnvrTWM2OD1zMDFOwG0> NV3MZmNvOjN6NESwN|g>
HuNS-1 M2nYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;YVosyOCEQvF2= NVH5O5dXPzJiaB?= MonpSG1UVw>? NEP0e2lKSzVyPUGwJO69VQ>? MYOyN|g1PDB|OB?=
IGROV1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPzV4YyOCEQvF2= MX:3NkBp NEHjXHdFVVOR Ml7iTWM2OD1zMDFOwG0> MYqyN|g1PDB|OB?=
J82 NIHKZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVmxNEDPxE1? NXLOXZZlPzJiaB?= MXjEUXNQ MlLiTWM2OD1zMDFOwG0> Mm\BNlM5PDRyM{i=
JM1 MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[xNEDPxE1? NXLGcZRjPzJiaB?= MlnGSG1UVw>? NW\5dFV[UUN3ME2xNEDPxE1? MXuyN|g1PDB|OB?=
Kato III M13CVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHMNVAh|ryP MXm3NkBp NF\xPWRFVVOR M3jHOWlEPTB;MUCg{txO NYn6[llpOjN6NESwN|g>
KHOS-240S NFLmbZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn6zNVAh|ryP MV23NkBp NGnkSXlFVVOR M{TnVWlEPTB;MUCg{txO M4LtOFI{QDR2MEO4
KM-12 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PjcFExKM7:TR?= MkexO|IhcA>? NXvWbHlYTE2VTx?= NHzDcYNKSzVyPUGwJO69VQ>? MUWyN|g1PDB|OB?=
KPL-1 Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M322dFExKM7:TR?= NV2y[YZWPzJiaB?= Mke2SG1UVw>? Mo\MTWM2OD1zMDFOwG0> MViyN|g1PDB|OB?=
KYSE-30 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL1c3A4OTBizszN M2S3VlczKGh? M2DOSmROW09? MoG2TWM2OD1zMDFOwG0> NGfkPJYzOzh2NECzPC=>
LNCaP NXPETnRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX:xNEDPxE1? NGDTcmk4OiCq MnvtSG1UVw>? NF30[4NKSzVyPUGwJO69VQ>? MlvRNlM5PDRyM{i=
MCF-7 M{HzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYKxNEDPxE1? NFLZflg4OiCq NHzhcHJFVVOR NV3p[4t2UUN3ME2xNEDPxE1? MV:yN|g1PDB|OB?=
MC-IXC M3;qOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HERlExKM7:TR?= M{\0dlczKGh? MkX2SG1UVw>? MkDkTWM2OD1zMDFOwG0> NGr1T28zOzh2NECzPC=>
MDA-MB-175 VII Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnu2NVAh|ryP MW[3NkBp NV3CfFBYTE2VTx?= NIjIdZhKSzVyPUGwJO69VQ>? MWeyN|g1PDB|OB?=
MDA-MB-468 NFftTJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLod2YyOCEQvF2= M3zkU|czKGh? M3HiPGROW09? NGfTTHdKSzVyPUGwJO69VQ>? Mn7RNlM5PDRyM{i=
MiaPaCa MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[xNEDPxE1? M1XsTVczKGh? MVLEUXNQ NXzRT5p{UUN3ME2xNEDPxE1? M{HLRlI{QDR2MEO4
Molt-4 NEC1fm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmxNEDPxE1? MWS3NkBp NEK5XYJFVVOR NXfDeXA3UUN3ME2xNEDPxE1? MmPENlM5PDRyM{i=
NCI-ADR/RES Mly0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmGwNVAh|ryP MYC3NkBp M1\1WGROW09? MXfJR|UxRTFyIN88US=> NHmwW2ozOzh2NECzPC=>
NCI-H69 M3TFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrCVFQyOCEQvF2= NHXoXXA4OiCq MXnEUXNQ M2KxOmlEPTB;MUCg{txO Mk\pNlM5PDRyM{i=
NCI-H82 NHjyN41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGmyW5gyOCEQvF2= MXK3NkBp NWTHSXY1TE2VTx?= NYj3NoN6UUN3ME2xNEDPxE1? M2XPOlI{QDR2MEO4
NCI-N87 NXPpR4tGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWOxNEDPxE1? NVvyV3lFPzJiaB?= M3XmWWROW09? NUXRZWFWUUN3ME2xNEDPxE1? MUiyN|g1PDB|OB?=
NCI-H146 NIfOcWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIL1W3oyOCEQvF2= NIXBe5I4OiCq NXrJUIFITE2VTx?= MVTJR|UxRTFyIN88US=> MonXNlM5PDRyM{i=
NCI-H157 NFjBXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoqwNVAh|ryP MYm3NkBp MmfMSG1UVw>? NHPYOWNKSzVyPUGwJO69VQ>? NYjHO3M6OjN6NESwN|g>
NCI-H187 NYe4PFgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ThfFExKM7:TR?= M3nsbVczKGh? M1X4R2ROW09? NEXZcIRKSzVyPUGwJO69VQ>? MW[yN|g1PDB|OB?=
NCI-H209 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETZXWcyOCEQvF2= M{fzeFczKGh? MUXEUXNQ NIrJTHJKSzVyPUGwJO69VQ>? MmXtNlM5PDRyM{i=
NCI-H226 M3XncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrSNVAh|ryP MXK3NkBp NEL2W|lFVVOR NYXiS2M4UUN3ME2xNEDPxE1? M2rNd|I{QDR2MEO4
NCI-H292 NUPjdmdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXixNEDPxE1? M1X6UVczKGh? NVSxVnoyTE2VTx?= NXTKbFlWUUN3ME2xNEDPxE1? NG\XbZAzOzh2NECzPC=>
NCI-H322 NFHab5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXGxNEDPxE1? NHnQVHg4OiCq NGfme|JFVVOR M4PNPWlEPTB;MUCg{txO MnLoNlM5PDRyM{i=
NCI-H358 NIXSdHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\VNVAh|ryP NWS1Zpl{PzJiaB?= Mk\iSG1UVw>? MlH1TWM2OD1zMDFOwG0> NUXmTohOOjN6NESwN|g>
NCI-H520 NFK2No9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTsNVAh|ryP MVW3NkBp NU\6U405TE2VTx?= MUfJR|UxRTFyIN88US=> M4C2SVI{QDR2MEO4
NCI-H526 NF7SdIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPkS5dXOTBizszN NFjrV5A4OiCq MkDzSG1UVw>? MVvJR|UxRTFyIN88US=> MnzGNlM5PDRyM{i=
NCI-H630 NILYTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUOxNEDPxE1? NXjnOXBVPzJiaB?= NV7ZT2c3TE2VTx?= M3;5d2lEPTB;MUCg{txO MXeyN|g1PDB|OB?=
NCI-H661 NV[wZ5R5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHu[GoxOTBizszN MU[3NkBp NIXWZmxFVVOR MV3JR|UxRTFyIN88US=> NVH1[IxiOjN6NESwN|g>
NCI-H716 NUTR[XdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3POXFExKM7:TR?= MVK3NkBp M{j4SGROW09? NILJW2NKSzVyPUGwJO69VQ>? M3jYS|I{QDR2MEO4
NCI-H1563 M3ux[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;Gc3ZlOTBizszN NXribmZGPzJiaB?= M4jCc2ROW09? Mkm5TWM2OD1zMDFOwG0> MYWyN|g1PDB|OB?=
NCI-H1792 M1S2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjjSYsyOCEQvF2= M2LWOFczKGh? NFXWWHdFVVOR NV3NRoJ4UUN3ME2xNEDPxE1? Mkf1NlM5PDRyM{i=
NCI-H2030 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVmxNEDPxE1? NIXrNHE4OiCq NFjBWnhFVVOR M4DrT2lEPTB;MUCg{txO MWCyN|g1PDB|OB?=
NCI-H2052 NVrOTW12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnraNVAh|ryP M2PSV|czKGh? MnvhSG1UVw>? MYDJR|UxRTFyIN88US=> NHjTeWkzOzh2NECzPC=>
NCI-H2122 MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVuxNEDPxE1? NYXiR49KPzJiaB?= NUT2co54TE2VTx?= MlLCTWM2OD1zMDFOwG0> NV;6TXJQOjN6NESwN|g>
NCI-H2228 M4Lq[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXexNEDPxE1? M1f0flczKGh? NV;QcpZCTE2VTx?= NX[5fWJrUUN3ME2xNEDPxE1? M1fwflI{QDR2MEO4
OE-19 NHnUU41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmxNEDPxE1? NYDzdnN5PzJiaB?= MYnEUXNQ M1T3N2lEPTB;MUCg{txO NYLMU3JUOjN6NESwN|g>
OE-21 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HNelExKM7:TR?= M3LkTlczKGh? MkHZSG1UVw>? NUDpSFNuUUN3ME2xNEDPxE1? M{jx[|I{QDR2MEO4
OE-33 NHz3RmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknhNVAh|ryP NHnBSYM4OiCq NWPaUHNJTE2VTx?= MoGwTWM2OD1zMDFOwG0> MlG1NlM5PDRyM{i=
OVCAR-3 M4X3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXGxNEDPxE1? MYq3NkBp MVnEUXNQ MYrJR|UxRTFyIN88US=> MljCNlM5PDRyM{i=
OVCAR-4 MnXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\GWXMyOCEQvF2= M1TONlczKGh? NH3OS4RFVVOR NVXBcmpoUUN3ME2xNEDPxE1? NX6z[nQzOjN6NESwN|g>
OVCAR-5 MmrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFqweJAyOCEQvF2= Mnn4O|IhcA>? NYnEVFcxTE2VTx?= NHvJ[YFKSzVyPUGwJO69VQ>? M2\GTlI{QDR2MEO4
P3HR-1 NW\Z[|RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUL0[VVYOTBizszN NUH6ZpVPPzJiaB?= MYLEUXNQ NGjMd3ZKSzVyPUGwJO69VQ>? NF;2OnAzOzh2NECzPC=>
PC-3 M3fhcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUKxNEDPxE1? MlfLO|IhcA>? MXrEUXNQ M3LUbWlEPTB;MUCg{txO M{fIPVI{QDR2MEO4
Raji M1PpSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfQNVAh|ryP MmnYO|IhcA>? NWGzOmlrTE2VTx?= NVnVXWF7UUN3ME2xNEDPxE1? NE\6UJczOzh2NECzPC=>
RD MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLMNHJuOTBizszN MlvyO|IhcA>? MnHHSG1UVw>? MYLJR|UxRTFyIN88US=> M{HxS|I{QDR2MEO4
RD-ES MnLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXexNEDPxE1? NEO3ToI4OiCq MnTlSG1UVw>? NEnKcIxKSzVyPUGwJO69VQ>? NWLONVc1OjN6NESwN|g>
RL MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYGxNEDPxE1? MnfVO|IhcA>? NEfhW|BFVVOR NYPHcWZNUUN3ME2xNEDPxE1? M1LJcVI{QDR2MEO4
SaOS2 MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInySI4yOCEQvF2= Ml\kO|IhcA>? M2nLcWROW09? Ml6xTWM2OD1zMDFOwG0> M4WxZVI{QDR2MEO4
SCC-9 MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\JSlExKM7:TR?= M{HFclczKGh? Mk\JSG1UVw>? M4jQSWlEPTB;MUCg{txO MUeyN|g1PDB|OB?=
SCC-12 NHTFTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVOxNEDPxE1? MoG3O|IhcA>? NEDCUYpFVVOR NVTVPGZXUUN3ME2xNEDPxE1? M4OwSlI{QDR2MEO4
SCC-13 NXnZN|U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHUWZNKOTBizszN NH\TVYM4OiCq NGHuSZpFVVOR NIPlSGJKSzVyPUGwJO69VQ>? NHnxZ|UzOzh2NECzPC=>
SCC-15 M2DwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVSzWFB6OTBizszN MmD5O|IhcA>? NI\LN4tFVVOR NFjOelJKSzVyPUGwJO69VQ>? NHrPTWIzOzh2NECzPC=>
SCC-25 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWWxNEDPxE1? M3;0VFczKGh? NVnObXRsTE2VTx?= MX\JR|UxRTFyIN88US=> NW\vSIE4OjN6NESwN|g>
SCLC-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\RTpIyOCEQvF2= NXLjOYJWPzJiaB?= MVvEUXNQ NFi3ZnBKSzVyPUGwJO69VQ>? M2HjNVI{QDR2MEO4
SF-268 MoDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHzd|cyOCEQvF2= MoLWO|IhcA>? M17JT2ROW09? NHrXd|NKSzVyPUGwJO69VQ>? NYHQNXhWOjN6NESwN|g>
SF-295 NW[1PFE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX[3VpozOTBizszN NG\pVoY4OiCq NXrUUllTTE2VTx?= M{nXVmlEPTB;MUCg{txO MnPxNlM5PDRyM{i=
SJRH30 NF3WSGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\uT4pPOTBizszN M{\Ce|czKGh? M2L4b2ROW09? NVT3UlJlUUN3ME2xNEDPxE1? Mof6NlM5PDRyM{i=
SK-BR-3 NH:3elZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXGxNEDPxE1? NWHIdlc4PzJiaB?= MoqySG1UVw>? NEfiN2xKSzVyPUGwJO69VQ>? M4qwOFI{QDR2MEO4
SK-LMS-1 NXj3OWhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXtcY0yOCEQvF2= MUS3NkBp M{fic2ROW09? MkLFTWM2OD1zMDFOwG0> NEi4c|EzOzh2NECzPC=>
SK-N-DZ NH7mcnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnqPGoyOCEQvF2= M2DT[|czKGh? MVTEUXNQ M{DQcGlEPTB;MUCg{txO MUSyN|g1PDB|OB?=
SK-N-F1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDDOIIyOCEQvF2= NF;Gd4k4OiCq MUPEUXNQ MWPJR|UxRTFyIN88US=> M4K3OlI{QDR2MEO4
SKOV-3 NYSxc4xCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXKxNEDPxE1? NUez[IMyPzJiaB?= NILxe25FVVOR NGP3WlBKSzVyPUGwJO69VQ>? MVuyN|g1PDB|OB?=
SK-UT-1 M3KyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\jVZZ2OTBizszN M1jDUlczKGh? M2G5d2ROW09? M3e2RmlEPTB;MUCg{txO NEPGUJczOzh2NECzPC=>
SN12C MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOxNEDPxE1? NVf1[nl7PzJiaB?= NXro[o9CTE2VTx?= MnfoTWM2OD1zMDFOwG0> NVfYepV7OjN6NESwN|g>
SNB-19 Ml;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXyydoFXOTBizszN NHvxc4I4OiCq MnPPSG1UVw>? M1W1S2lEPTB;MUCg{txO M1\mblI{QDR2MEO4
SNU-5 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDPNVAh|ryP MV23NkBp MYLEUXNQ MY\JR|UxRTFyIN88US=> MXyyN|g1PDB|OB?=
SNU-16 M1XLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXqxNEDPxE1? NY\WU5B1PzJiaB?= MXPEUXNQ NWHtUHlLUUN3ME2xNEDPxE1? NX[3e|JrOjN6NESwN|g>
SNU-398 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTLNVAh|ryP MWi3NkBp MoDjSG1UVw>? Mn\GTWM2OD1zMDFOwG0> NXewPWdiOjN6NESwN|g>
SNU-449 NYjZTXR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;GNVExKM7:TR?= NUPBWWF6PzJiaB?= NIL4SmxFVVOR NGPES3FKSzVyPUGwJO69VQ>? NEO2elYzOzh2NECzPC=>
SR NV\YcpJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\K[mhTOTBizszN NFLZcpg4OiCq M1jjNmROW09? MmPDTWM2OD1zMDFOwG0> MUeyN|g1PDB|OB?=
ST486 NXjEeZpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYCxNEDPxE1? NF;z[YE4OiCq MVrEUXNQ NGXCTldKSzVyPUGwJO69VQ>? M{Szd|I{QDR2MEO4
SW579 NHXTWHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHXU40yOCEQvF2= NELYUZE4OiCq NEX4UHpFVVOR MnjkTWM2OD1zMDFOwG0> NUHZZZR[OjN6NESwN|g>
SW684 NGXr[3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUOxNEDPxE1? M{\rPVczKGh? NX\LVo1PTE2VTx?= MYrJR|UxRTFyIN88US=> MVWyN|g1PDB|OB?=
SW-780 MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWKxNEDPxE1? Mn\SO|IhcA>? MoXISG1UVw>? MnzPTWM2OD1zMDFOwG0> NUHx[YxxOjN6NESwN|g>
SW900 M33DNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXiNVAh|ryP NGnaSm04OiCq NVjMTY4yTE2VTx?= MmTVTWM2OD1zMDFOwG0> NVnMWHZFOjN6NESwN|g>
SW1088 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjZd4QyOCEQvF2= M3O0U|czKGh? MXPEUXNQ NIrEOpJKSzVyPUGwJO69VQ>? NXviT5FxOjN6NESwN|g>
SW1463 NYHRfWRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWixNEDPxE1? M361SlczKGh? MVPEUXNQ MnzzTWM2OD1zMDFOwG0> NUjzSJRjOjN6NESwN|g>
SW1990 NGLPOI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrEZZIyOCEQvF2= NH3FZpE4OiCq MX7EUXNQ NX2zRYRpUUN3ME2xNEDPxE1? MnruNlM5PDRyM{i=
T47D M1PEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHIT2wyOCEQvF2= NFnlOVg4OiCq MmfYSG1UVw>? MofKTWM2OD1zMDFOwG0> MY[yN|g1PDB|OB?=
TE381.T NHXDNGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDPZosyOCEQvF2= MnrhO|IhcA>? MUXEUXNQ MVHJR|UxRTFyIN88US=> NYjJOGFPOjN6NESwN|g>
TK-10 MlqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOxNEDPxE1? NEnvS5Q4OiCq M4T1cmROW09? NVLwRlVuUUN3ME2xNEDPxE1? M4XUNFI{QDR2MEO4
U2OS NFHjR2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTsNVAh|ryP MU[3NkBp MVfEUXNQ MXLJR|UxRTFyIN88US=> M3;E[FI{QDR2MEO4
U251 NYi0fFRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\tfYloOTBizszN M1HSV|czKGh? NWPUS|JzTE2VTx?= M1\3N2lEPTB;MUCg{txO MofZNlM5PDRyM{i=
UACC-812 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDSNVAh|ryP M1H2XlczKGh? MVvEUXNQ MYPJR|UxRTFyIN88US=> NH6weZMzOzh2NECzPC=>
YAPC NF3GdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTy[5QyOCEQvF2= NEfP[YU4OiCq M1TTSWROW09? M1:xPWlEPTB;MUCg{txO NHHDNHYzOzh2NECzPC=>
ZR-75-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVmxNEDPxE1? MXW3NkBp MUnEUXNQ MmD5TWM2OD1zMDFOwG0> MXuyN|g1PDB|OB?=
A375 M3;5eGZ2dmO2aX;uJIF{e2G7 Mmj5NU4zKM7:TR?= NWnUO4I6PCCq M3XFTWROW09? M1S4e2lvcGmkaYTpc44hd2ZicHjvd5Bpd3K7bHH0bY9vKG:oIF3FT{whTVKNLDDhcoQhWz[S NFe1UHozOjN6OUS3NS=>
YUSIT1 NU\sPJNYTnWwY4Tpc44h[XO|YYm= NE\lNJNFVVOR NH7uN3pz\WS3Y3XkJJNmdnOrdHn2bZR6KHerdHigTWM2OCB-IECuOUDPxE1? NULpU2VWOjJ|OEm0O|E>
MeWo NYDwOWZ5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnLhSG1UVw>? NWrpR|RpUUN3MDC9JFk5PyCwTR?= M{HVb|I3ODF6NUK0
WiDr MmPNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYDEUXNQ M2fhWmlEPTBiPTC3OkBvVQ>? M4TDd|I3ODF6NUK0
Colo-205 NHn4c3lHfW6ldHnvckBie3OjeR?= M3nWTVEh|ryP Ml\IOEBl MULEUXNQ M1OzT2lv\HWlZXSgZUBpcWeqbImgZ49ueGG{YXLs[UBkd22yYXP0bY9vKHCqZX7veJlx\Q>? M1vWXlI2OzhzMUWy
RBW-1 M{TwfGZ2dmO2aX;uJIF{e2G7 NWf6S3V4OSEQvF2= M2W4OmROW09? MkjXUo8hemWmdXP0bY9vKG:oIF3lb{AyNzJicHjvd5Bpd3K7bHH0bY9v MorrNlQ5QDV4OUC=
RBO-1 NFHTfGxHfW6ldHnvckBie3OjeR?= NWLtZ5dTOSEQvF2= NH70XVBFVVOR M37ke2lvcGmkaYTpc44hd2ZiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44> Moe2NlQ5QDV4OUC=
RBO-2 M{PEUWZ2dmO2aX;uJIF{e2G7 MYCxJO69VQ>? NGm0TVBFVVOR NV;RRnJoUW6qaXLpeIlwdiCxZjCgUYVsKDFxMjDwbI9{eGixconsZZRqd25? NHewbG8zPDh6NU[5NC=>
RBOW MnewSpVv[3Srb36gZZN{[Xl? NGPLZlAyKM7:TR?= MWnEUXNQ NHvZd2FKdmirYnn0bY9vKG:oIDDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>? NXPIZ49oOjR6OEW2PVA>
M257 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTVflQyODBibl2= NGjFO3U4OiCq NWLNOVNnTG:nczDuc5QhcW6qaXLpeEBxem:uaX\ldoF1cW:wIH;mJG0zPTdiY3XscEBp[XKkb4XybY5oKHerbHSgeJlx\SCEUlHG NW[zPVJYOjN|MUe0OFY>
LCP NXK4OoU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXKNVAxKG6P M1HSNlczKGh? MoLKTY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;uJI9nKEyFUDDj[YxtKGijcnLveZJqdmdiQmLBSkBXPjByUjDteZRidnSjdHnvci=> MX2yN|MyPzR2Nh?=
WM266 NX7LW3E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDy[WtiOTByIH7N MoPvO|IhcA>? MW\Jcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36gc4YhX01{Nk[gZ4VtdCCqYYLic5VzcW6pIFLSRWYhXjZyMVSgcZV1[W62YYTpc44> MVeyN|MyPzR2Nh?=
M257 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3HXVN2OTByIH7N MVO3NkBp NVX6dVRWTG:nczDuc5QhcW6qaXLpeEBGWktzLUKgdIhwe3Cqb4L5cIF1cW:wIHnuJG0zPTdiY3XscEBp[XKkb4XybY5oKHerbHSgeJlx\SCEUlHG MY[yN|MyPzR2Nh?=
LCP Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jQbVExOCCwTR?= NWjYbnV[PzJiaB?= NWnwO4xEUW6qaXLpeEBGWktzLUKgdIhwe3Cqb4L5cIF1cW:wIHnuJGxEWCClZXzsJIhiemKxdYLpcochSlKDRjDWOlAxWiCvdYThcpRifGmxbh?= NY[3S4o3OjN|MUe0OFY>
WM266 NEXaWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWGxNFAhdk1? MWK3NkBp NFzxc4dKdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gW20zPjZiY3XscEBp[XKkb4XybY5oKEKUQV[gWlYxOERibYX0ZY51[XSrb36= NGDxXGYzOzNzN{S0Oi=>

... Click to View More Cell Line Experimental Data

In vivo Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. [1]

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (57.74 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
8 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 519.56
Formula

C23H20F3N5O2S2

CAS No. 1195765-45-7
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01723202 Active, not recruiting Follicular Thyroid Cancer|Insular Thyroid Cancer|Papillary Thyroid Cancer|Recurrent Thyroid Cancer Manisha Shah|National Comprehensive Cancer Network|Ohio State University Comprehensive Cancer Center November 7, 2012 Phase 2
NCT02672358 Not yet recruiting Non-Small-Cell Lung Cancer Novartis Pharmaceuticals|Novartis October 2017 Phase 2
NCT02447939 Withdrawn Melanoma GlaxoSmithKline May 2017 Phase 1
NCT02967692 Not yet recruiting Melanoma Novartis Pharmaceuticals|Novartis February 2017 Phase 3
NCT02858921 Not yet recruiting Melanoma Melanoma Institute Australia|Merck Sharp & Dohme Corp.|Novartis February 2017 Phase 2
NCT03026517 Recruiting Melanoma Memorial Sloan Kettering Cancer Center|Massachusetts General Hospital|Weill Medical College of Cornell University January 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products

Tags: buy Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) supplier | purchase Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) cost | Dabrafenib (GSK2118436) manufacturer | order Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID